|
|
FDADocs 5/5/2008 | 0 (0) | 20 | 1 | 0 | English
??? ??? ??? ???Resources for FDA Apheresis Review Criteria??? Regulations in the Code of...FDA Review of Apheresis SubmissionsJudy Ellen CiaraldiBS, MT(ASCP)SBB, CQA(ASQ ... more>>
GovernmentDocs 5/5/2008 | 0 (0) | 73 | 1 | 0 | English
FDA MEDIA TELECONFERENCE FOOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 Sept. 27, 2007, 2 p.m. EDT Coordinator: Welcome and thank you for standing by. At this time all parties are in a ... more>>
FDADocs 5/8/2008 | 0 (0) | 110 | 1 | 0 | English
Food Reviews International, 2(1), 79-107(1986)IRRADIATION O FOODS- F AN FDA PERSPECTIVE GEORGE H. PAULI and CLYDE A. TAKEGUCHIFood and Dmg Administration Center for Food Safety and Applied ... more>>
FDADocs 5/5/2008 | 0 (0) | 77 | 1 | 0 | English
Case 8:03-cv-01663-RAL-MSSDocument 64Filed 09/14/2004Page 1 of 13UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION UNITED STATES OF AMERICA, Pl... ... more>>
FDADocs 5/9/2008 | 0 (0) | 32 | 1 | 0 | English
GovernmentDocs 5/5/2008 | 0 (0) | 44 | 1 | 0 | English
Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLPDocument issued on: June 2004U.S. Department of Health and Human Services Food and Drug ... more>>
FDADocs 5/9/2008 | 0 (0) | 73 | 1 | 0 | English
Judy Staffa, co-leads, presiding. PRESENT: SOLOMON IYASU JUDY STAFFA LANA PAULS GERALD DAL PAN FDA FDA ... more>>
GovernmentDocs 5/5/2008 | 0 (0) | 63 | 1 | 0 | English
DEPARTMENT OF HEALTH & HUMAN SERVICESPublic Health ServiceFood and Drug Administration Rockville, MD 20857NDA 18-662/S046Hoffman-La Roche Inc. Attention: Joanna Wau... ... more>>
FDADocs 5/8/2008 | 0 (0) | 11 | 1 | 0 | English
Cancer Nanotechnology: New Opportunities for Targeted TherapiesFDA Public Meeting October 10, 2006Piotr Grodzinski, Ph.D. Director, Nanotechnology for Cancer Programs Office of Technology and ... more>>
FDADocs 5/9/2008 | 0 (0) | 62 | 1 | 0 | English
Evaluation of Biotechnology-Derived Pharmaceuticals (July 1997) (http://www.fda.gov/cder/guidance ... more>>
FDADocs 5/9/2008 | 0 (0) | 37 | 1 | 0 | English
DIVISION OF DRUG ONCOLOGY PRODUCTS Briefing Document for Oncology Drug Advisory Committee NDA: Applicant: Established Drug Name: 21-986, N-000 Bristol-Myers Squibb Dasatinib (BMS-3... ... more>>
FDADocs 5/9/2008 | 0 (0) | 23 | 1 | 0 | English
DIVISION OF DRUG ONCOLOGY PRODUCTS Briefing Document for Oncology Drug Advisory Committee NDA: Applicant: Established Drug Name: 21-986, N-000 Bristol-Myers Squibb Dasatinib (BMS-3... ... more>>
lbuckler 8/15/2008 | 0 (0) | 248 | 1 | 0 | 0
FDA sends non-compliance letter to cell therapy company Regenerative Sciences Inc (doing business as Regenexx).
See online at http:www.fda.govcbercomplregen072508.htm ... more>>
FDADocs 5/5/2008 | 0 (0) | 19 | 1 | 0 | English
FDA/PQRI Workshop on A Drug Quality System in the 21st CenturyApril 22-24, 2003 Renaissance Washington DC Hotel Washington, DCTable of ContentsWorkshop Information Goals and Objectives ... more>>
FDADocs 5/5/2008 | 0 (0) | 17 | 1 | 0 | English
Fenwal Automated Devices: FDA Licensing Workshop August 2007Agenda??? ALYX??? ??? ??? ??? Double LR RBCs LR RBCs/Plasma Non-LR Double RBCs (limited launch) Plasma (not in distribution ... more>>
| | | |
| results / page 15/25/50 |
Page: 3 of 33
|
3...
|
|